MedPath

Comparison of extracorporeal liver support systems MARS and SPAD in a cross over desig

Phase 4
Conditions
Acute and acut-on-chronic liver failure
K70
K77
T86.4
K71
K72
K73
K74
K75
K76
Registration Number
DRKS00000371
Lead Sponsor
Klinik für Anästhesiologie und IntensivtherapieUniversitätsklinikum Jena
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
32
Inclusion Criteria

acute or acute-on-chronic liver failure
- Serum bilirubin > 8-10 mg/dl ( 136-171 µmol/l) und plasma disappearance rate of indocyanine green (PDRICG) < 8-10 %

Exclusion Criteria

Age below 18 years

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes of serum bilirubin concentrations, blood samples before and after albumin dialysis
Secondary Outcome Measures
NameTimeMethod
Changes of other laboratory parameters before and after each cycle of albumin dialysis:<br>blood samples for laboratory parameters (albumin binding capacity, bile acids, indols, phenols, ammonia, Liver parameters (ASAT, ALAT, GLDH, GGT, AP), albumin, total proteins, lactate, creatinine, urea, blood count (hb, hct, WBC, thrombocytes), coagulation parameters (prothrombin ratio, PTT, factor V, fibrinogen, antithrombin), electrolytes (sodium, potassium, calcium), cytokines, vasoactive substances, etc.) || classification of hepatic encephalopathy grade before and after each cycle of albumin dialysis (HE-grade; in awake patients additionaly determination with:Hepatic Encephalopathy Scoring Algorithm) || organ dysfunction before and after each cycle of albumin dialysis (SOFA-Score, catecholamine dose, cardiac output (assessment with PiCCO) || plasma disappearance rate of indocyanine green (PDR-ICG; assessment with LiMON) before and after each cycle of albumin dialysis
© Copyright 2025. All Rights Reserved by MedPath